Home/Pipeline/Veto Cell CAR‑T for Lymphoma

Veto Cell CAR‑T for Lymphoma

Diffuse Large B‑Cell Lymphoma

PreclinicalActive

Key Facts

Indication

Diffuse Large B‑Cell Lymphoma

Phase

Preclinical

Status

Active

Company

About Cell Source

Innovative Veto Cell platform enabling donor‑free transplants and durable CAR‑T cancer therapies.

View full company profile

Therapeutic Areas

Oncology Hematology Transplantation Autoimmune